⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845047 | 1.00 | — | — | |
| SCHEMBL2815214 | 1.00 | — | — | |
| SCHEMBL9653531 | 0.82 | — | — | |
| SCHEMBL6815908 | 0.79 | CES2 (0.43) | — | |
| SCHEMBL13009934 | 0.79 | CES2 (0.43) | — | |
| SCHEMBL3220577 | 0.77 | — | — | |
| SCHEMBL8198712 | 0.75 | — | — | |
| SCHEMBL4160974 | 0.75 | — | — | |
| SCHEMBL9655883 | 0.74 | CES2 (0.39) | — | |
| SCHEMBL12360950 | 0.73 | CA9 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869363-B | 5-membered and bicyclic heterocyclic amides as ROCK inhibitors | 百时美施贵宝公司 | 2024-01-05 | — | — | CN | disclosed |
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-13 | — | — | US | disclosed |
| CN-110612298-B | Thienopyridines and benzothiophenes as IRAK4 inhibitors | 百时美施贵宝公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220356179-A1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3621960-B1 | THIENOPYRIDINES AND BENZOTHIOPHENES USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3621960-B1 | THIENOPYRIDINES AND BENZOTHIOPHENES USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11078197-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3652168-B1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210147406-A1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| US-10829496-B2 | Thienopyridines and benzothiophenes useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3621960-A1 | THIENOPYRIDINES AND BENZOTHIOPHENES USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-110869363-A | 5-membered and bicyclic heterocyclic amides as ROCK inhibitors | 百时美施贵宝公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20200062777-A1 | THIENOPYRIDINES AND BENZOTHIOPHENES USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200062777-A1 | THIENOPYRIDINES AND BENZOTHIOPHENES USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-27 | — | — | US | disclosed |
| WO-2018209012-A1 | THIENOPYRIDINES AND BENZOTHIOPHENES USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-11-15 | — | — | WO | disclosed |
| US-7763623-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763623-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2007087204-A2 | HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA | SCHERING CORPOORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION | 2007-07-26 | — | — | US | disclosed |
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION | 2007-07-26 | — | — | US | disclosed |